Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Table 3 Effect of TSF and placebo on Scr, BUN, UAER, eGFR and ln plasma L-FABP levels in patients with macroalbuminuria

Parameters	Groups	Baseline	Week 12	Week 24
24 h UP (g/24 h)	TSF	1.0 ± 0.7	0.5 ± 0.5^a	0.5 ± 0.5^a
24 h UP (g/24 h)	Placebo	0.9 ± 0.6	0.6 ± 0.6	0.7 ± 0.7
BUN (mmol/L)	TSF	6.0 ± 1.7	6.0 ± 1.7	6.0 ± 1.9
BUN (mmol/L)	Placebo	6.1 ± 1.1	6.9 ± 1.6	7.2 ± 1.7
Scr (μmol/L)	TSF	74.9 ± 20.7	72.6 ± 22.6	73.5 ± 18.9
Scr (μmol/L)	Placebo	79.4 ± 18.2	84.0 ± 17.4	83.1 ± 16.4
eGFR (ml/min/1.73 m²)	TSF	104.1 ± 32.8	102.7 ± 37.7	97.3 ± 25.8
eGFR (ml/min/1.73 m²)	Placebo	96.2 ± 30.0	91.3 ± 30.1	92.3 ± 32.2
ln plasma L-FABP (μg/ml)	TSF	1.7 ± 1.0	1.3 ± 1.3	1.5 ± 0.9
ln plasma L-FABP (μg/ml)	Placebo	1.6 ± 1.2	0.8 ± 1.4	1.2 ± 1.0

All values expressed as mean ± SD
^a P < 0.05 compared with baseline of the same group (Paired t test)
Abbreviations: BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, ln-serum L-FABP ln-transformed serum liver-type fatty acid binding protein, Scr serum creatinine, UAER urinary albumin excretion rate